EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S18	8	S16 and trifluormethylphenyl	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	OFF	2007/10/29 14:13
S17	0	S16 and trifluormethylphenyl and acetamido	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	OFF	2007/10/29 14:13
S16	9230	MEISSNER.in. or perkins.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	OFF	2007/10/29 14:13
S3	101	"4220775"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	OFF	2007/10/29 15:03
S19	1607	(514/80.icls. or 514/80.ccls. or 514/284.icls. or 514/284.ccls. or 546/23.icls. or 546/77.icls or 546/23.ccls. or 546/77.ccls)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	OFF	2007/10/29 15:06
L1	1704	(514/80.icls. or 514/80.ccls. or 514/284.icls. or 514/284.ccls. or 546/23.icls. or 546/77.icls or 546/23.ccls. or 546/77.ccls or 546/23.fs. or 546/77.fs or 514/80.fs. or 514/284.fs.)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	OFF	2007/10/29 15:08
L4	3	l1 and trifluoromethyl and acetamide and L3	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	OFF	2007/10/29 15:09
L3	9230	MEISSNER.in. or perkins.in.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	OFF	2007/10/29 15:09
L6	6	l1 and trifluoromethyl.clm. and acetamide and androst.clm.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	OFF	2007/10/29 15:11

EAST Search History

L5	64	l1 and trifluoromethyl.clm. and acetamide	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	OFF	2007/10/29 15:11
L2	136	l1 and trifluoromethyl and acetamide	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	ADJ	OFF	2007/10/29 15:11

```
=> dup rem l58 l44
L44 HAS NO ANSWERS
FILE 'HCAPLUS' ENTERED AT 13:40:26 ON 29 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 Jan 2007  VOL 146 ISS 6
FILE LAST UPDATED: 28 Jan 2007  (20070128/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.
PROCESSING COMPLETED FOR L58
PROCESSING COMPLETED FOR L44
L59             4 DUP REM L58 L44 (0 DUPLICATES REMOVED)
                  ANSWERS '1-4' FROM FILE HCAPLUS

=> d l59 1-4 ibib abs ed hitstr hitind

L59  ANSWER 1 OF 4  HCAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2004:1015853  HCAPLUS  Full-text
DOCUMENT NUMBER:          142:1359
TITLE:                    Identification and synthesis of androgen
                          receptor modulators and therapeutic uses
                          thereof
INVENTOR(S):              Meissner, Robert S.; Perkins, James J.
PATENT ASSIGNEE(S):       Merck & Co., Inc., USA
SOURCE:                   PCT Int. Appl., 165 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------
     --------
     WO 2004100874         A2    20041125    WO 2004-US13787
                                                                     2004
                                                                     0503
     WO 2004100874         A3    20060126
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG,
             ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
             KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
             MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL,
             PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
             TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
             ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH,
             CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
             MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI,
```

	CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004238238		A1	20041125	AU 2004-238238
				2004
				0503
CA 2524409		A1	20041125	CA 2004-2524409
				2004
				0503
EP 1622567		A2	20060208	EP 2004-751257
				2004
				0503
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
CN 1784236		A	20060607	CN 2004-80012253
				2004
				0503
JP 2006528686		T	20061221	JP 2006-532555
				2004
				0503
US 2006241107		A1	20061026	US 2005-551975
				2005
				1005
PRIORITY APPLN. INFO.:				US 2003-468579P P
				2003
				0507
				WO 2004-US13787 W
				2004
				0503

OTHER SOURCE(S): MARPAT 142:1359

GI



I

AB Compds. of structural formula (I) as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of agonizing the androgen receptor in a patient, and in particular the method wherein the androgen receptor is antagonized in the prostate of a male patient or in the uterus of a female patient and agonized in bone and/or muscle tissue. Method for the synthesis of those compds., as well as techniques for the screening of androgen receptor modulation capacity of those compds. are exemplified. These compds. are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including: osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, post-menopausal symptoms in women, female sexual dysfunction, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, arthritis and joint repair, alone or in combination with other active agents. In addition, these compds. are useful as pharmaceutical composition ingredients alone and in combination with other active agents.

796885-62-6P 796885-63-7P 796885-64-8P
796885-65-9P 796885-66-0P 796885-67-1P
796885-68-2P 796885-69-3P 796885-70-6P
796885-71-7P 796885-72-8P 796885-73-9P
796885-74-0P 796885-75-1P 796885-76-2P
796885-77-3P 796885-78-4P 796885-79-5P
796885-80-8P 796885-81-9P 796885-82-0P
796885-83-1P 796885-84-2P 796885-85-3P
796885-86-4P 796885-87-5P 796885-88-6P
796885-89-7P 796885-90-0P 796885-91-1P
796885-92-2P 796885-93-3P 796885-94-4P
796885-95-5P 796885-96-6P 796885-97-7P
796885-98-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(identification and synthesis of androgen receptor modulators and therapeutic uses thereof)

RN 154112-31-9 HCAPLUS
CN 3-Thiophenecarboxamide, N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Refer (Witzel, structure search, P-102) attached

RN 154112-38-6 HCAPLUS
CN Benzamide, 2-fluoro-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154112-39-7 HCAPLUS
CN Benzamide, 4-cyano-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-

2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154112-41-1 HCAPLUS
CN 2-Thiophenecarboxamide, N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Refer (Witzel, structure search, P-108) attached

RN 154112-55-7 HCAPLUS
CN Propanamide, 2-methyl-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 156470-59-6P 156470-60-9P 156470-61-0P 156470-62-1P
156470-63-2P 156470-64-3P 156470-65-4P 156470-66-5P
156470-67-6P 156470-68-7P 156470-69-8P 156470-70-1P
156470-71-2P 156470-72-3P 156470-73-4P 156470-74-5P
156470-75-6P 156470-76-7P 156470-77-8P 156470-78-9P
156470-79-0P 156470-80-3P 156470-81-4P 156470-82-5P
156470-83-6P 156470-84-7P 156470-85-8P 156470-86-9P
156470-87-0P 156470-88-1P 156470-89-2P 156470-90-5P
156470-91-6P 156470-92-7P 156470-93-8P 156470-94-9P
156470-95-0P 156470-96-1P 156470-97-2P 156470-98-3P
156470-99-4P 156471-00-0P 156471-01-1P 156471-02-2P
156471-03-3P 156471-04-4P 156471-05-5P 156471-06-6P
156471-07-7P 156471-08-8P 156471-09-9P 156471-10-2P
156471-11-3P **156471-12-4P** **156471-13-5P**
156471-14-6P 156471-15-7P 156471-16-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as testosterone 5α-reductase inhibitor)

L59 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:457778 HCAPLUS Full-text
DOCUMENT NUMBER: 121:57778
TITLE: 17-Amino-substituted 4-azasteroid 5α-reductase inhibitors
INVENTOR(S): Witzel, Bruce E.; Bergman, Jeffrey P.; Tolman, Richard L.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9323038	A1	19931125	WO 1993-US4633	1993 0517
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9342506	A	19931213	AU 1993-42506	1993 0517
AU 675225	B2	19970130		
EP 649431	A1	19950426	EP 1993-911332	1993 0517
EP 649431	B1	19990811		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 07508034	T	19950907	JP 1993-503780	1993 0517
AT 183193	T	19990815	AT 1993-911332	1993 0517
US 5639741	A	19970617	US 1995-338472	1995 0320

PRIORITY APPLN. INFO.: US 1992-886057 A2

1992
0520

WO 1993-US4633 A
1993
0517

OTHER SOURCE(S): MARPAT 121:57778
GI



I

AB Novel 4-azasteroids, useful as 5α-reductase inhibitors, are claimed, as well as pharmaceutically acceptable salts and formulations thereof. The compds. have formula I [A = amide-containing sidechains Q1, Q2, Q3; R1 = H, Me, Et; R2 = H, C1-20 alkyl; R3 = H, (un)substituted alk(en)yl, (hetero)aryl, cycloalk(en)yl; R4 = H, C1-20 alkyl, (un)substituted (hetero)aryl; R5 = H, C1-12 alkyl; W = CO, SO2; x = 1-25; optional Δ1 and/or Δ5]. I are effective in inhibiting testosterone 5α-reductase(s) (no data) and are thus useful in the treatment of a number of hyperandrogenic conditions including benign prostatic hypertrophy, acne, seborrhea, female hirsutism, and male and female pattern baldness (alopecia). Over 230 specific compds. are claimed by name, syntheses of several are described, and identifying NMR peaks for approx. 25 compds. are also given. For example, 4-methyl-3-oxo-5α-4-azaandrostan-17β- carboxaldehyde was converted to the oxime, followed by hydrogenation, to give its 17β-aminomethyl analog. Amidation of this with 12-(isopropylthio)dodecanoic acid using DCC and DMAP gave I [R1 = Me, A = CH2NHCO(CH2)11SCHMe2, double bonds absent].

ED Entered STN: 06 Aug 1994

IT **154112-24-0P 154112-25-1P 154112-26-2P**
154112-27-3P 154112-28-4P 154112-29-5P
154112-30-8P 154112-31-9P 154112-32-0P
154112-33-1P 154112-34-2P 154112-35-3P
154112-36-4P 154112-37-5P 154112-38-6P
154112-39-7P 154112-40-0P 154112-41-1P
154112-42-2P 154112-43-3P 154112-44-4P
154112-45-5P 154112-46-6P 154112-47-7P
154112-48-8P 154112-49-9P 154112-50-2P
154112-51-3P 154112-52-4P 154112-53-5P
154112-54-6P 154112-55-7P 154112-56-8P
154112-57-9P 154112-58-0P 154112-59-1P
154112-60-4P 154112-61-5P 154112-62-6P
154112-63-7P 154112-64-8P 154112-65-9P
154112-66-0P 154112-67-1P 154112-68-2P
154112-69-3P 154112-70-6P 154112-71-7P
154112-72-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as 5α-reductase inhibitor)

RN 154112-24-0 HCAPLUS

Structure Search



RN 154112-38-6 HCAPLUS
CN Benzamide, 2-fluoro-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154112-39-7 HCAPLUS
CN Benzamide, 4-cyano-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154112-40-0 HCAPLUS
CN Benzo[b]thiophene-3-acetamide, N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

RN 154112-46-6 HCAPLUS
CN Benzenepropanamide, β-methyl-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154112-47-7 HCAPLUS
CN Benzamide, 2,3-difluoro-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154112-48-8 HCAPLUS
CN Benzamide, 2-methyl-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154112-49-9 HCAPLUS
CN Benzamide, 2,3-dimethyl-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154112-50-2 HCAPLUS
CN 2-Propenamide, 3-phenyl-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 154112-51-3 HCAPLUS
CN 2-Butenamide, 3-methyl-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX

NAME)

Absolute stereochemistry.



RN 154112-52-4 HCAPLUS
CN Benzamide, 3,4-dimethoxy-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154112-53-5 HCAPLUS
CN Acetamide, 2-(acetyloxy)-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154112-54-6 HCAPLUS

CN Butanamide, 4-(2-nitrophenoxy)-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154112-55-7 HCAPLUS

CN Propanamide, 2-methyl-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154112-56-8 HCAPLUS

CN Benzamide, 4-(phenylmethoxy)-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154112-71-7 HCAPLUS
CN Benzamide, 2,6-difluoro-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154112-72-8 HCAPLUS
CN Benzamide, 2,3-difluoro-N-[(4aR,4bS,6aS,7S,9aS,9bS,11aR)-10-fluoro-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-trimethyl-2-oxo-1H-indeno[5,4-f]quinolin-7-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IC ICM A61K031-435
ICS C07D221-02
CC 32-4 (Steroids)
Section cross-reference(s): 1, 2
IT 86307-05-3P 154110-65-3P 154110-66-4P 154110-67-5P
154110-68-6P 154110-69-7P 154110-70-0P 154110-71-1P
154110-72-2P 154110-73-3P 154110-74-4P 154110-75-5P
154110-76-6P 154110-77-7P 154110-78-8P 154110-79-9P
154110-80-2P 154110-81-3P 154110-82-4P 154110-83-5P
154110-84-6P 154110-85-7P 154110-86-8P 154110-87-9P
154110-88-0P 154110-89-1P 154110-90-4P 154110-91-5P
154110-92-6P 154110-93-7P 154110-94-8P 154110-95-9P
154110-96-0P 154110-97-1P 154110-98-2P 154110-99-3P
154111-00-9P 154111-01-0P 154111-02-1P 154111-03-2P
154111-04-3P 154111-05-4P 154111-06-5P 154111-07-6P
154111-08-7P 154111-09-8P 154111-10-1P 154111-11-2P